Healthcare Services

Neurology Clinical Trials Industry Expansion Forecast Showing Market Size of $8.04 Billion by 2030 at 6.7% CAGR

April 3, 2026April 3, 2026 by Marketing Posting

The Business Research Company’s 2026 market reports include new capabilities such as market attractiveness scoring and analysis, total addressable market analysis, company scoring matrix, interactive excel data dashboard, improved supply chain analysis, upcoming startups in the market, and overview of key products, aimed at improving the depth, usability, and strategic value of the insights delivered.

What Is The Expected Market Size Of The Neurology Clinical Trials Market From 2026 To 2030?

The neurology clinical trials market has experienced strong expansion in recent years. It is projected to grow from $5.8 billion in 2025 to $6.21 billion in 2026, demonstrating a compound annual growth rate (CAGR) of 7.0%. The growth observed in the historic period is due to factors such as an increase in neurological disease prevalence, the expansion of pharmaceutical research pipelines, greater investment in neurology drug development, the availability of advanced imaging tools, and rising participation in clinical research.

The neurology clinical trials market size is projected for substantial expansion in the coming years. This market is set to reach $8.05 billion by 2030, exhibiting a compound annual growth rate (CAGR) of 6.7%. The anticipated growth during this period stems from factors such as the increasing application of AI-driven trial analytics, a growing need for quicker trial execution, the proliferation of patient-centric trial models, greater incorporation of remote monitoring technologies, and an enhanced focus on uncommon neurological conditions. Key developments anticipated in the forecast period encompass the wider embrace of adaptive clinical trial designs, increased utilization of digital tools for patient monitoring, a sharpened emphasis on biomarker-driven neurology trials, the broadening of decentralized clinical trial frameworks, and a heightened significance placed on generating real-world evidence.

Download the Free Sample Report to Explore Key Market Insights:

https://www.thebusinessresearchcompany.com/sample.aspx?id=25847&type=smp

Which Growth Drivers Are Contributing To The Progress Of The Neurology Clinical Trials Market?

The rising incidence of neurological conditions is projected to boost the neurology clinical trials market in the future. Neurological disorders are health issues that impact the brain, spinal cord, or nerves, thus disrupting the normal functioning of the nervous system. The primary reason for the rise in these disorders is the aging demographic, as elderly individuals are more prone to age-related ailments like Alzheimer’s and Parkinson’s disease. Neurology clinical trials play a crucial role in addressing neurological disorders by evaluating novel treatments, medications, or interventions to enhance diagnosis, alleviate symptoms, decelerate disease progression, and improve patient results. For example, data from September 2024, provided by the Australian Institute of Health and Welfare, an Australia-based government body, indicates that the population of Australians suffering from dementia is anticipated to more than double, climbing from 411,100 in 2023 to 849,300 by 2058. Furthermore, by 2058, it is estimated that 315,500 men and 533,800 women will be affected by dementia. Consequently, the increasing occurrence of neurological disorders is propelling the expansion of the neurology clinical trials market.

Which Segments Are Included In The Analysis Of The Neurology Clinical Trials Market?

The neurology clinical trials market covered in this report is segmented –

1) By Phase: Phase I, Phase II, Phase III, Phase IV

2) By Study Design: Interventional, Observational, Expanded Access

3) By Indication: Epilepsy, Parkinson’s Disease (PD), Huntington’s Disease, Stroke, Traumatic Brain Injury (TBI), Amyotrophic Lateral Sclerosis (ALS), Multiple Sclerosis, Other Indications

4) By End-User: Hospitals, Clinics, Research Institutes, Other End- Users

Subsegments:

1) By Phase I: Drug Safety Evaluation, Pharmacokinetics Assessment, Dosage Range Finding, Tolerability Studies

2) By Phase II: Efficacy Evaluation, Dose Response Studies, Therapeutic Effectiveness, Biomarker Identification

3) By Phase III: Large Scale Efficacy Studies, Safety Monitoring, Comparative Effectiveness, Risk Benefit Analysis

4) By Phase IV: Post Marketing Surveillance, Long Term Safety Follow Up, Real World Evidence Collection, Quality Of Life Assessment

What Trends Are Advancing Progress In The Neurology Clinical Trials Market?

Major companies active within the neurology clinical trials market are concentrating on developing innovative solutions, including monoclonal antibodies, aimed at specific neurological pathways to enhance treatment efficacy and expedite the creation of novel therapies. A monoclonal antibody refers to a molecule produced in a laboratory, engineered to identify and bind to particular proteins or antigens, commonly utilized to precisely target disease mechanisms in treatments and diagnostics. For instance, in July 2024, Eli Lilly and Company, a pharmaceutical company based in the U.S., launched Kisunla (donanemab-azbt) for the treatment of early symptomatic Alzheimer’s disease. This treatment works to slow cognitive and functional decline, thereby giving eligible patients more time to sustain independence and participate in daily life. It operates by targeting and reducing brain amyloid plaques, and clinical trials have indicated up to a 35% slowing of disease progression against placebo in those with less advanced forms of the disease.

Which Key Industry Participants Are Active In The Neurology Clinical Trials Market?

Major companies operating in the neurology clinical trials market are AbbVie Inc., Sanofi S.A., Novartis AG, Eli Lilly and Company, Teva Pharmaceutical Industries Ltd., IQVIA Holdings Inc., Biogen Inc., ICON plc., Syneos Health, Charles River Laboratories International Inc., Parexel International Corporation, CMIC Holdings Co. Ltd., Medpace Holdings Inc., PSI CRO AG., Supernus Pharmaceuticals Inc., Worldwide Clinical Trials LLC., Ergomed plc., Biotrial S.A.S., Clinilabs Drug Development Corporation, Lindus Health Ltd.

Read the full neurology clinical trials market report here:

https://www.thebusinessresearchcompany.com/report/neurology-clinical-trials-global-market-report

What Are The Leading Geographic Regions In The Neurology Clinical Trials Market?

North America was the largest region in the neurology clinical trials market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the neurology clinical trials market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Request A Tailored Neurology Clinical Trials Market Research Report For Competitive Advantage:

https://www.thebusinessresearchcompany.com/customise?id=25847&type=smp

Browse Through More Reports Similar to the Global Neurology Clinical Trials Market 2026, By The Business Research Company

Interventional Neurology Devices And Equipment Global Market Report

https://www.thebusinessresearchcompany.com/report/interventional-neurology-devices-and-equipment-global-market-report

Neuroprosthetics Global Market Report

https://www.thebusinessresearchcompany.com/report/neuroprosthetics-global-market-report

Neuroscience Antibodies And Assays Global Market Report

https://www.thebusinessresearchcompany.com/report/neuroscience-antibodies-and-assays-global-market-report

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795